Vistagen therapeutics stock.

Feb 7, 2023 · VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.05 per share a year ago. Dec 1, 2023 · Stock Information Stock Quote & Chart; Historical Data; Analyst Coverage; Press Releases; Events; SEC Filings All SEC Filings; Annual Reports; Quarterly Results; Section 16 Filings; Corporate Governance Executive Team; Board Committees; Documents & Charters See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 22, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen, the Company), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) …Medical, dental and vision premiums are paid at 100% for employees. Competitive wages. Unlimited paid time off (PTO) Paid holidays. Flexible work locations. Employee stock purchase plan. Follow us on LinkedIn. Apply to join Vistagen today. If you are interested in joining the Vistagen team, but do not see a job that matches your skill set ...

Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ...

Medical - Biomedical and Genetics. $0.095B. $0.001B. VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in ...

Apr 20, 2023 · SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of America (ADAA) Conference in Washington, D.C., that further supporting ... View 13F filing holders of VistaGen Therapeutics Inc. 13F filings are submitted quarterly to the SEC by hedge funds and other investment managers.Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are …Nov 29, 2023 · See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, ... Vistagen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged ...

Vistagen Therapeutics’ fast-acting nasal spray drug, fasedienol, hit primary and secondary goals of an abbreviated late-stage study in social anxiety disorder. Vistagen’s stock price rocketed ...

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.07 per share a year ago.

VistaGen Therapeutics, Inc. Common Stock (VTGN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst markets.businessinsider.com - November 14 at 6:25 PM: VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript finance.yahoo.com - November 11 at 5:51 PMTrack VistaGen Therapeutics Inc (VTGN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVistagen’s fasedienol (PH94B) is a first-in-class, rapid-onset investigational neuroactive pherine nasal spray in Phase 3 clinical development for acute treatment of social anxiety disorder (SAD). Designed for intranasal administration in low microgram doses, the proposed novel mechanism of action (MOA) of fasedienol is fundamentally ...Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate update and reported financial results for its fiscal year 2023 third quarter ended December 31, 2022.

4 hours ago · Related Content: Anxiety-Focused Stock Vistagen Therapeutics Is An Undervalued Late-Stage Neurology Player: Analyst. Aside from one negative Phase 3 study, PALISADE-1, which was impacted by the ... Vistagen Therapeutics’ core goal is to radically improve mental health and well-being worldwide. To that end, Vistagen is developing an innovative pipeline of CNS medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders that are disrupting the lives of tens of millions of ...VTGN stock forecast for 2023 – 2027. Last updated: September 26, 2023. VTGN. VistaGen Therapeutics, Inc. 5.30 D 0.95% (0.05)With FDA feedback confirming the acceptable use of the LSAS as a primary efficacy endpoint, Vistagen is positioned to finalize key components of its potential New Drug Application (NDA)-enabling development program for fasedienol for treatment of SAD. Dr. Michael R. Liebowitz, a Columbia University psychiatrist, former director and founder …Shares of VistaGen Therapeutics ( VTGN -6.17%) were soaring 22.1% as of 11:27 a.m. EST on Thursday. The big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy ...Nov 15, 2022 · The upgrade of VistaGen Therapeutics, Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in ... Compare stocks to their industry peers at U.S. News Best Stocks. Money. Credit Cards. Best Of. ... VistaGen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in ...

Vistagen Therapeutics, Inc. 3.6900 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Passion and purpose to transform patient journeys in anxiety and depression. VistaGen Therapeutics' is developing an innovative pipeline of Central Nervous System medications with the potential to establish new standards of care, safety, and effectiveness in the treatment of a variety of serious anxiety, depression and other CNS disorders. The latest price target for Vistagen Therapeutics ( NASDAQ: VTGN) was reported by Stifel on Tuesday, November 14, 2023. The analyst firm set a price target for 12.00 expecting VTGN to rise to ...... therapeutics with the potential to be faster-acting, with fewer side effects ... Social anxiety nasal spray study results make Peninsula biotech's stock shoot up ...Nov 9, 2023 · MT. Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating. Oct. 17. MT. Maxim Downgrades VistaGen Therapeutics to Hold From Buy. 2022. MT. Jefferies Downgrades VistaGen Therapeutics to Hold from Buy, Adjusts Price Target to $0.20 from $8. Source Headline; Retail investors are Vistagen Therapeutics, Inc.'s (NASDAQ:VTGN) biggest owners and were rewarded after market cap rose by US$12m last week finance.yahoo.com - November 29 at 8:15 AM: Vistagen climbs as Stifel launches at Buy on anxiety prospects msn.com - November 14 at 6:25 PM: Anxiety-Focused Stock …About the VistaGen Therapeutics, Inc. stock forecast. As of 2023 November 29, Wednesday current price of VTGN stock is 3.600$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. VistaGen Therapeutics stock price as been showing a rising tendency so we believe …SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of …Find real-time VTGN - Vistagen Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

See today’s best-performing stocks on TipRanks >> Based on VistaGen Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $179.6 ...

VTGN has an Altman Z-Score of -5.47 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for VistaGen Therapeutics, Inc. (VTGN) stock, including valuation metrics, financial numbers, share information and more.

VistaGen Therapeutics on Monday posted positive topline data from the Phase III PALISADE-2 trial, showing that its investigational nasal spray fasedienol met its primary endpoint, strongly easing distress among patients with social anxiety disorder. The market reacted enthusiastically to the news, sending VistaGen’s stock soaring around …VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system.The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. VistaGen Therapeutics Inc 50-day moving average is $3.73.VistaGen Therapeutics (NASDAQ:VTGN) drops one position to rank fourth for the week. Data shows 16.6% of the float short, in line with last week’s report. The cost to borrow on shares falls from ...SOUTH SAN FRANCISCO - Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today announced new data, presented at the 2023 Anxiety and Depression Association of …Aug 15, 2023 · 3.5900. +0.2400. +7.16%. VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript August 13, 2023 Operator: Greetings, and welcome to the Vistagen Therapeutics Fiscal Year 2024 ... Oct 2, 2023 · Nov 09, 2023. Vistagen to Present at Stifel 2023 Healthcare Conference. Nov 08, 2023. Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences. Nov 07, 2023. Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023. Nov 06, 2023. About the VistaGen Therapeutics, Inc. stock forecast. As of 2023 November 29, Wednesday current price of VTGN stock is 3.600$ and our data indicates that the asset price has been in an uptrend for the past 1 year (or since its inception).. VistaGen Therapeutics stock price as been showing a rising tendency so we believe …If you want to keep up to date on the stock market you have a device in your pocket that makes that possible. Your phone can track everything finance-related and help keep you up to date on the world markets.The latest price target for . Vistagen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on September 5, 2023.The analyst firm set a price target for $30.00 expecting VTGN to rise to within ...Stock Price Forecast. The 2 analysts offering 12-month price forecasts for Vistagen Therapeutics Inc have a median target of 12.00, with a high estimate of 12.00 and a low estimate of 12.00. The ...

Vistagen Therapeutics, Inc. 3.6900 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...Advertisement Vistagen Therapeutics, Inc. (VTGN) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 3.6500 +0.0600 (+1.67%) At close: 04:00PM EST 3.6700 +0.02 (+0.55%) After... VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.05 per share a year ago.William Blair initiated coverage on VistaGen Therapeutics Inc (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing next-generation treatment options for social anxiety ...Instagram:https://instagram. carnival corporation stock priceai with no filterbest mortgage lenders in mainealpha stock price See the latest Vistagen Therapeutics Inc stock price (VTGN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Cerevel's stock doubled to $25.20 a share after the company put out the data in a press release. ... recently initiated coverage of VistaGen Therapeutics and pegged the company as a hidden gem. november 2023 soybean futuresschlumberger oil Analysts at Stifel recently initiated coverage on Vistagen Therapeutics Inc (NASDAQ: VTGN), emphasizing the potential of its lead asset, fasedienol, in clinical development for social anxiety ... best futures trading platform for mac Vistagen Therapeutics, Inc. 3.6500 +0.0600 +1.67%: TRENDING. 1. ... As U.S. stocks sit on hefty gains at the close of a rollercoaster year, investors are eyeing factors that could sway equities in ...Vistagen Therapeutics, Inc. 3.6900 ... is selling $2 billion of stock in Las Vegas Sands Corp. so the family can acquire a majority stake in the Dallas Mavericks NBA franchise from Mark Cuban.Most ...Psychedelic therapy, also known as psychedelic-assisted psychotherapy (PAP), combines traditional talk therapy with a psychedelic substance, such as LSD, psilocybin, ayahuasca, or MDMA.